Serum antibodies associated with complex inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 19, Issue 7, 2013, Pages 1499-1505

  Elkadri, Abdul A ^a,b   Stempak, Joanne M ^a   Walters, Thomas D ^b   Lal, Simon ^a   Griffiths, Anne M ^b   Hillary Steinhart, A ^a   Silverberg, Mark S ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Biomarkers; Complex; Crohn's disease; Inflammatory bowel disease; Serology; Ulcerative colitis

Indexed keywords

ANTIBODY; BACTERIUM ANTIBODY; FLAGELLIN ANTIBODY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; NEUTROPHIL CYTOPLASMIC ANTIBODY; OUTER MEMBRANE PROTEIN C ANTIBODY; SACCHAROMYCES CEREVISIAE ANTIBODY; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ANTIBODY BLOOD LEVEL; ANUS DISEASE; ARTICLE; COLON RESECTION; CONTROLLED STUDY; CROHN DISEASE; DISEASE DURATION; ENTEROPATHY; HUMAN; ILEOCOLONIC DISEASE; INTESTINE PERFORATION; INTESTINE SURGERY; MAJOR CLINICAL STUDY; PERIANAL DISEASE; PRIORITY JOURNAL; SEROLOGY; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; CANADA; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; FLAGELLIN; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MALE; PREVALENCE; PROGNOSIS; SACCHAROMYCES CEREVISIAE; YOUNG ADULT;

EID: 84879080975     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0b013e318281f2a1     Document Type: Article

References (48)

1. Duchmann R, May E, Heike M, et al. T cell specificity and cross reactivity towards enterobacteria, bacteroides, bifidobacterium, and antigens from resident intestinal flora in humans. Gut. 1999;44:812-818.
2. Landers CJ, Cohavy O, Misra R, et al. Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto-and microbial antigens. Gastroenterology. 2002;123:689-699.
3. Giaffer MH, Clark A, Holdsworth CD. Antibodies to Saccharomyces cerevisiae in patients with Crohn's disease and their possible pathogenic importance. Gut. 1992;33:1071-1075.
4. Main J, McKenzie H, Yeaman GR, et al. Antibody to Saccharomyces cerevisiae (bakers' yeast) in Crohn's disease. BMJ. 1988;297:1105-1106.
5. Barnes RM, Allan S, Taylor-Robinson CH, et al. Serum antibodies reactive with Saccharomyces cerevisiae in inflammatory bowel disease: is IgA antibody a marker for Crohn's disease? Int Arch Allergy Appl Immunol. 1990;92:9-15.
6. Koutroubakis IE, Petinaki E, Mouzas IA, et al. Anti-Saccharomyces cerevisiae mannan antibodies and antineutrophil cytoplasmic autoantibodies in Greek patients with inflammatory bowel disease. Am J Gastroenterol. 2001;96:449-454.
7. Linskens RK, Mallant-Hent RC, Groothuismink ZM, et al. Evaluation of serological markers to differentiate between ulcerative colitis and Crohn's disease: pANCA, ASCA and agglutinating antibodies to anaerobic coccoid rods. Eur J Gastroenterol Hepatol. 2002;14:1013-1018.
8. Quinton JF, Sendid B, Reumaux D, et al. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut. 1998;42:788-791.
9. Vermeire S, Peeters M, Vlietinck R, et al. Anti-Saccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD, and intestinal permeability: a study in IBD families. Inflamm Bowel Dis. 2001;7:8-15.
10. Halfvarson J, Standaert-Vitse A, Jarnerot G, et al. Anti-Saccharomyces cerevisiae antibodies in twins with inflammatory bowel disease. Gut. 2005;54:1237-1243.
11. Peeters M, Joossens S, Vermeire S, et al. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am J Gastroenterol. 2001;96:730-734.
12. Vasiliauskas EA, Plevy SE, Landers CJ, et al. Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup. Gastroenterology. 1996;110:1810-1819.
13. Walker LJ, Aldhous MC, Drummond HE, et al. Anti-Saccharomyces cerevisiae antibodies (ASCA) in Crohn's disease are associated with disease severity but not NOD2/CARD15 mutations. Clin Exp Immunol. 2004;135:490-496.
14. Vasiliauskas EA, Kam LY, Karp LC, et al. Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut. 2000;47:487-496.
15. Mow WS, Vasiliauskas EA, Lin YC, et al. Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology. 2004;126:414-424.
16. Sandborn WJ, Loftus EV Jr, Colombel JF, et al. Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn's disease. Inflamm Bowel Dis. 2001;7:192-201.
17. Klebl FH, Bataille F, Bertea CR, et al. Association of perinuclear antineutrophil cytoplasmic antibodies and anti-Saccharomyces cerevisiae antibodies with Vienna classification subtypes of Crohn's disease. Inflamm Bowel Dis. 2003;9:302-307.
18. Sandborn WJ, Landers CJ, Tremaine WJ, et al. Association of antineutrophil cytoplasmic antibodies with resistance to treatment of left-sided ulcerative colitis: results of a pilot study. Mayo Clin Proc. 1996;71:431-436.
19. Sandborn WJ, Landers CJ, Tremaine WJ, et al. Antineutrophil cytoplasmic antibody correlates with chronic pouchitis after ileal pouch-anal anastomosis. Am J Gastroenterol. 1995;90:740-747.
20. Zholudev A, Zurakowski D, Young W, et al. Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn's disease and ulcerative colitis: diagnostic value and correlation with disease phenotype. Am J Gastroenterol. 2004;99:2235-2241.
21. Dubinsky MC, Lin YC, Dutridge D, et al. Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progression. Am J Gastroenterol. 2006;101:360-367.
22. Lodes MJ, Cong Y, Elson CO, et al. Bacterial flagellin is a dominant antigen in Crohn disease. J Clin Invest. 2004;113:1296-1306.
23. Targan SR, Landers CJ, Yang H, et al. Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease. Gastroenterology. 2005;128:2020-2028.
24. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19(suppl A):5-36.
25. Arnott ID, Landers CJ, Nimmo EJ, et al. Sero-reactivity to microbial components in Crohn's disease is associated with disease severity and progression, but not NOD2/CARD15 genotype. Am J Gastroenterol. 2004;99:2376-2384.
26. Bossuyt X. Serologic markers in inflammatory bowel disease. Clin Chem. 2006;52:171-181.
27. Riis L, Vind I, Vermeire S, et al. The prevalence of genetic and serologic markers in an unselected European population-based cohort of IBD patients. Inflamm Bowel Dis. 2007;13:24-32.
28. Amre DK, Lu SE, Costea F, et al. Utility of serological markers in predicting the early occurrence of complications and surgery in pediatric Crohn's disease patients. Am J Gastroenterol. 2006;101:645-652.
29. Dassopoulos T, Frangakis C, Cruz-Correa M, et al. Antibodies to Saccharomyces cerevisiae in Crohn's disease: Higher titers are associated with a greater frequency of mutant NOD2/CARD15 alleles and with a higher probability of complicated disease. Inflamm Bowel Dis. 2007;13:143-151.
30. Cohavy O, Bruckner D, Gordon LK, et al. Colonic bacteria express an ulcerative colitis pANCA-related protein epitope. Infect Immun. 2000;68:1542-1548.
31. Devlin SM, Yang H, Ippoliti A, et al. NOD2 variants and antibody response to microbial antigens in Crohn's disease patients and their unaffected relatives. Gastroenterology. 2007;132:576-586.
32. Sostegni R, Daperno M, Ercole E, et al. Detection of anti-Saccharomyces cerevisiae antibodies in Crohn's disease: is it a reliable diagnostic and prognostic marker? Dig Liver Dis. 2001;33:755-761.
33. Smith BR, Arnott ID, Drummond HE, et al. Disease location, anti-Saccharomyces cerevisiae antibody, and NOD2/CARD15 genotype influence the progression of disease behavior in Crohn's disease. Inflamm Bowel Dis. 2004;10:521-528.
34. Reese GE, Constantinides VA, Simillis C, et al. Diagnostic precision of anti-Saccharomyces cerevisiae antibodies and perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel disease. Am J Gastroenterol. 2006;101:2410-2422.
35. Buckland MS, Mylonaki M, Rampton D, et al. Serological markers (anti-Saccharomyces cerevisiae mannan antibodies and antineutrophil cytoplasmic antibodies) in inflammatory bowel disease: diagnostic utility and phenotypic correlation. Clin Diagn Lab Immunol. 2005;12:1328-1330.
36. Ruemmele FM, Targan SR, Levy G, et al. Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. Gastroenterology. 1998;115:822-829.
37. Bansi DS, Chapman RW, Fleming KA. Prevalence and diagnostic role of antineutrophil cytoplasmic antibodies in inflammatory bowel disease. Eur J Gastroenterol Hepatol. 1996;8:881-885.
38. Kull K, Salupere R, Uibo R, et al. Antineutrophil cytoplasmic antibodies in Estonian patients with inflammatory bowel disease. Prevalence and diagnostic role. Hepatogastroenterology. 1998;45:2132-2137.
39. Oudkerk Pool M, Ellerbroek PM, Ridwan BU, et al. Serum antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease are mainly associated with ulcerative colitis. A correlation study between perinuclear antineutrophil cytoplasmic autoantibodies and clinical parameters, medical, and surgical treatment. Gut. 1993;34:46-50.
40. Makharia GK, Sachdev V, Gupta R, et al. Anti-Saccharomyces cerevisiae antibody does not differentiate between Crohn's disease and intestinal tuberculosis. Dig Dis Sci. 2007;52:33-39.
41. Maunder RG, Greenberg GR, Hunter JJ, et al. Psychobiological subtypes of ulcerative colitis: pANCA status moderates the relationship between disease activity and psychological distress. Am J Gastroenterol. 2006;101:2546-2551.
42. Deusch K, Oberstadt K, Schaedel W, et al. p-ANCA as a diagnostic marker in ulcerative colitis. Adv Exp Med Biol. 1993;336:527-531.
43. Dubinsky MC, Kugathasan S, Mei L, et al. Increased immune reactivity predicts aggressive complicating Crohn's disease in children. Clin Gastroenterol Hepatol. 2008;6:1105-1111.
44. Lichtenstein GR, Targan SR, Dubinsky MC, et al. Combination of genetic and quantitative serological immune markers are associated with complicated Crohn's disease behavior. Inflamm Bowel Dis. 2011;17:2488-2496.
45. Seow CH, Stempak JM, Xu W, et al. Novel anti-glycan antibodies related to inflammatory bowel disease diagnosis and phenotype. Am J Gastroenterol. 2009;104:1426-1434.
46. Hui T, Landers C, Vasiliauskas E, et al. Serologic responses in indeterminate colitis patients before ileal pouch-anal anastomosis may determine those at risk for continuous pouch inflammation. Dis Colon Rectum. 2005;48:1254-1262.
47. Fleshner P, Ippoliti A, Dubinsky M, et al. Both preoperative perinuclear antineutrophil cytoplasmic antibody and anti-CBir1 expression in ulcerative colitis patients influence pouchitis development after ileal pouch-anal anastomosis. Clin Gastroenterol Hepatol. 2008;6:561-568.
48. Tyler AD, Milgrom R, Xu W, et al. Antimicrobial Antibodies Are Associated With a Crohn's Disease-Like Phenotype After Ileal Pouch-Anal Anastomosis. Clin Gastroenterol Hepatol. 2012;10:507-512.e1.